This occurs in an OG activation by several mechanisms—such as point mutations, for example, constitutive protein activation, as in KRAS mutation; gene amplification overexpression, HER2 amplification in breast cancer; and chromosomal translocations making fusion proteins, such as BCR-ABL in chronic myeloid leukemia. The gene discussed is ERBB2; the disease is breast carcinoma.